Thermo Fisher stock analysis
Thermo Fisher (TN8) Stock Price & Analysis
TN8 Stock Chart & Stats
- Day’s Range
- EUR 639.00 - EUR 652.80
- 52-Week Range
- EUR 375.00 - EUR 652.80
- Previous Close
- EUR 640.80
- Volume
- N/A
- Average Volume (3M)
- 301
- Market Cap
- EUR 239.81B
- Enterprise Value
- EUR 285.86B
- Total Cash (Recent Filing)
- EUR 6.06B
- Total Debt (Recent Filing)
- EUR 41.37B
- Price to Earnings (P/E)
- 37.8
- Beta
- 0.57
- Next Earnings
- Feb 04, 2027 (Est.)
- EPS Estimate
- 6.39
- Next Dividend Ex-Date
- Dec 15, 2026
- Dividend Yield
- 0.24%
Bulls Say, Bears Say
Bulls Say
Diversified Recurring-revenue Model
Revenue combines repeat-purchase consumables, service contracts and workflow products with instruments that generate downstream pull-through. This mix, spanning pharma, research, clinical and industrial customers, supports recurring demand and reduces reliance on any single end market.
Strong Cash Generation
Substantial operating and free cash flow, with strong conversion from earnings, gives Thermo Fisher resources to fund capital investment, product development, debt repayment and shareholder returns. This cash-generation profile supports resilience and strategic flexibility across business cycles.
Innovation And Bioproduction Positioning
Product innovation across AI-enabled microscopy, sequencing, diagnostics and mass spectrometry broadens Thermo Fisher’s capabilities. Its stated leadership in bioproduction technologies also aligns the portfolio with long-term pharmaceutical and biotechnology manufacturing needs.
Bears Say
Meaningful Leverage
Meaningful debt and elevated leverage increase fixed financial obligations and reduce flexibility relative to a lightly levered balance sheet. They can constrain capital allocation and make the company more sensitive to slower growth, refinancing conditions or sustained interest expense.
Muted Reagent Demand
Weakness in bioscience and genetic science reagents limits growth in a recurring, consumables-oriented part of the portfolio. If biotech spending takes longer to recover, subdued demand could restrain organic growth and leave more reliance on stronger bioproduction and service areas.
Specialty Diagnostics Weakness
A reported decline in Specialty Diagnostics shows that performance is uneven across Thermo Fisher’s businesses despite broader company growth. Continued weakness in this segment could offset gains elsewhere and require stronger execution to restore momentum in diagnostics.
Thermo Fisher News
TN8 FAQ
What was Thermo Fisher’s price range in the past 12 months?
What is Thermo Fisher’s market cap?
When is Thermo Fisher’s upcoming earnings report date?
How were Thermo Fisher’s earnings last quarter?
Is Thermo Fisher overvalued?
Does Thermo Fisher pay dividends?
What is Thermo Fisher’s EPS estimate?
How many shares outstanding does Thermo Fisher have?
What happened to Thermo Fisher’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Thermo Fisher?
What is the TipRanks Smart Score and how is it calculated?
Thermo Fisher Stock Smart Score
Company Description
Thermo Fisher
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Marc N. Casper
- Employees
- 125,000
- Website
- www.thermofisher.com
- Address
- 168 Third Avenue, Waltham, MA, 02451, US
Thermo Fisher (TN8) Earnings & Revenues
TN8 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Thermo Fisher delivered broad-based revenue, profit, margin, cash flow, and organic growth improvements; exceeded prior guidance; raised full-year revenue, EPS, and free cash flow guidance; and reported continued momentum in pharma, biotech, analytical instruments, AI, clinical research, and bioproduction. The main challenges were flat academic and government revenue, a decline in reported Specialty Diagnostics revenue, muted reagent demand, unfavorable mix, and some Pharma Services timing between the third and fourth quarters.
View all DE:TN8 earnings summariesTN8 Net sales Breakdown
- 54.01% Laboratory Products and Biopharma Services
- 22.46% Life Sciences Solutions
- 17.40% Analytical Instruments
- 10.52% Specialty Diagnostics
TN8 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 2 | 4 |
| Technical Analysis | 3 | 2 | 4 |
| Moving Averages | 12 | 0 | 0 |
